CLS BTU B Stock Overview
Engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Clinical Laserthermia Systems AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 6.20 |
| 52 Week High | SEK 6.20 |
| 52 Week Low | SEK 5.92 |
| Beta | 0.35 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.22% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CLS BTU B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | n/a | -0.06% | -1.0% |
| 1Y | n/a | -1.1% | 13.3% |
Return vs Industry: Insufficient data to determine how CLS BTU B performed against the Swedish Medical Equipment industry.
Return vs Market: Insufficient data to determine how CLS BTU B performed against the Swedish Market.
Price Volatility
| CLS BTU B volatility | |
|---|---|
| CLS BTU B Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CLS BTU B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CLS BTU B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 17 | Dan Mogren | www.clinicallaser.se |
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment.
Clinical Laserthermia Systems AB (publ) Fundamentals Summary
| CLS BTU B fundamental statistics | |
|---|---|
| Market cap | SEK 47.04m |
| Earnings (TTM) | -SEK 70.90m |
| Revenue (TTM) | SEK 10.83m |
4.3x
P/S Ratio-0.7x
P/E RatioIs CLS BTU B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLS BTU B income statement (TTM) | |
|---|---|
| Revenue | SEK 10.83m |
| Cost of Revenue | SEK 8.46m |
| Gross Profit | SEK 2.37m |
| Other Expenses | SEK 73.27m |
| Earnings | -SEK 70.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -9.03 |
| Gross Margin | 21.88% |
| Net Profit Margin | -654.91% |
| Debt/Equity Ratio | 3.0% |
How did CLS BTU B perform over the long term?
See historical performance and comparison